I believe that institutional holding of TXB should increase, especially with the stock rising well above that $5 price point that seems to be so important for most institutions to become holders. The data you have seems to indicate that this is the case.
I think insider holdings are normal for this type of company, too, with normal purchase and sales activity occurring for a biotech. I get the following information about purchases/sales:
CARLUCCI FRANK C 10,000 09/26/97 5.00 D
COLWELL RITA R 1,000 09/25/97 5.00 D
BURNS PATRICK OWEN -695 11/25/96 3.63 D
MUELLER STEPHEN L -14,286 05/22/96 6.13 O
WELCH JOSEPH M -18,667 05/20/96 5.14 VP
DIXON RICHARD A F -14,286 05/15/96 5.08 OD
MAGGIO EDWARD T 19,665 06/30/95 1.41 D
MAGGIO EDWARD T 49,164 06/30/95 1.41 D
CRUIKSHANK ROBERT J 10,000 06/05/95 1.81 D
THOMSON JAMES A 2,000 12/15/94 1.50 D
Looks good to me. Looks like a number of the insiders are willing to put their own money into the company. The few sales are only to be expected as runups in the stock or their own needs (buy a house, etc.) often drive these things. |
